Illustration of light blue neurons with white amyloid plaques accumulating on their axons.
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial

The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.

The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.

amyloid
Infographic showing how neurodegenerative diseases have long been associated with aggregations of apparently toxic proteins
Infographic: Secret Lives of Neurodegeneration-Linked Proteins
Catherine Offord | Aug 1, 2022
Maligned peptides such as the Alzheimer’s-associated amyloid precursor protein may have critical roles in the healthy brain.
Amyloid plaques on axons of neurons
The Misunderstood Proteins of Neurodegeneration
Catherine Offord | Aug 1, 2022
The normal functions of peptides that aggregate in Alzheimer’s, Parkinson’s, and Huntington’s have been largely overlooked by scientists, but some argue that they are critical for understanding the development of disease.
An APP-knockout neuron (right) shows extended axonal and reduced dendritic growth compared with a normal mouse neuron (left). Scale bar 50 µm.
Amyloid Precursor Protein Linked to Brain Development Mechanisms
Catherine Offord | Dec 1, 2021
Researchers provide evidence that the Alzheimer’s-associated protein calibrates a signaling pathway that is conserved across the animal kingdom.
Illustration of neurons in white with myelin in blue
Repurposed Drug Reverses Signs of Alzheimer’s in Mice, Human Cells
Jef Akst | Oct 12, 2021
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.
Updated
blue and white sign for the entrance to the FDA that says U.S. Department of Health and Human Services Food and Drug Administration
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Kerry Grens | Jun 7, 2021
A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.
Eli Lilly Claims New Drug Can Slow Alzheimer’s-Related Decline
Lisa Winter | Mar 16, 2021
Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.
bace1 alzheimer's disease gga3 axon neuron
Alzheimer’s-Linked Mutation Causes Blockages in Neurons
Ian Le Guillou | Nov 20, 2020
The variant causes a buildup of BACE1 protein in axons in cultured neurons and mice. Researchers say it might be time to rethink failed trials that inhibit BACE1 to treat the neurodegenerative disease.
a patient getting blood drawn for testing
First Alzheimer’s Blood Test Rolled Out for Clinical Use in US
Shawna Williams | Nov 2, 2020
The test will be a cheaper and more accessible alternative to currently available diagnostic tools, researchers say.
amyloid-beta amyloid plaque alzheimer's disease coarse-grained neurodegeneration ab40 ab42
Newly Found Alzheimer’s Plaque Type Linked to Early-Onset Disease
Ian Le Guillou | Sep 28, 2020
These “coarse-grained” plaques resemble those that clog up the brain’s blood vessels in a different disease, pointing to links between the vascular system and the neurodegenerative disease.
Poor Sleep Linked with Future Amyloid-β Build Up
Abby Olena | Sep 11, 2020
Accumulation of the protein was more likely to be found in the brains of people who slept less well years earlier, according to a new study.
tau p-tau217 amyloid amyloid-beta alzheimer's disease blood test
Experimental Blood Test Could Flag Alzheimer’s
Kerry Grens | Jul 29, 2020
New studies show that elevated levels of a form of tau called p-tau217 can accurately distinguish Alzheimer’s disease from other forms of dementia, and perhaps even predict it.
Robert Moir
Iconoclastic Alzheimer’s Researcher Robert Moir Dies
Shawna Williams | Jan 2, 2020
The 58-year-old was best known for uncovering evidence of a link between pathogens and the neurodegenerative disease.
APOE Mutation Linked to Protection From Alzheimer’s: Case Study
Catherine Offord | Nov 5, 2019
A woman whose DNA suggested she’d develop early-onset dementia staved off cognitive decline for decades.
Chemist Christopher Dobson Dies
Ashley Yeager | Sep 16, 2019
The University of Cambridge scholar’s research on folding proteins advanced scientists’ understanding of illnesses, such as Alzheimer’s disease, Parkinson’s disease, and type 2 diabetes.
human macrophage
Image of the Day: Alzheimer’s Genes
Nicoletta Lanese | Aug 19, 2019
Mutations within the MS4A gene cluster have been linked to changes in protein levels that affect disease risk.
Rapidly Flashing Lights and Sounds Reduces Alzheimer’s in Mice
Jef Akst | Mar 15, 2019
Exposing mice to an hour of 40-hertz stimuli every day for a week reduced levels of amyloid-β plaques and tau protein, and improved cognition.
Gum Disease Could Drive Alzheimer’s: Study
Ashley Yeager | Jan 24, 2019
An enzyme of the bacteria Porphyromonas gingivalis has been found in the brains of patients with the disorder, and causes neurodegeneration in mice.
Alzheimer’s Drug Slows Symptoms, Reduces Plaques
Kerry Grens | Jul 26, 2018
In a clinical trial, patients on the highest injected dose had 30 percent less cognitive decline over time than people on a placebo.
Exosomes in Blood Indicate Mild TBI: Study
Ashley Yeager | Jul 13, 2018
Levels of tau, amyloid-β 42, and IL-10 extracted from extracellular vesicles that started out in the brain were higher in military personal suffering head injuries compared with healthy soldiers.